C
Carlsmed
Biotech & Life Sciences · United States · Founded 2018 · IPO 2025
Carlsmed is personalized surgical implants for patients with debilitating spine deformities MoreLess
Carlsmed operates in the medical technology sector, focusing on personalized spine surgery solutions. The company leverages patient data and advanced digital technologies to create customized surgical plans and 3D-printed spine fusion devices, known as aprevo implants. These implants are tailored to each patient's unique anatomical needs, ensuring optimal surgical outcomes. Carlsmed serves healthcare professionals, particularly spine surgeons, and their patients who require spine fusion surgeries. The business model revolves around the integration of patient imaging data, surgeon preferences, and digital design to produce bespoke surgical solutions. Revenue is generated through the sale of these personalized implants and associated surgical planning services. By providing highly customized medical devices, Carlsmed aims to improve surgical precision and patient recovery times.
Keywords: personalized spine surgery, 3D-printed implants, patient-specific plans, digital technologies, spine fusion devices, healthcare professionals, surgical precision, medical technology, patient data, bespoke surgical solutions.
Talent graph
Carlsmed's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Carlsmed has talent and traffic
team presence
across markets
Market sentiment
What the market is saying about Carlsmed
An AI-synthesized read of the highest-engagement posts about Carlsmed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Carlsmed on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.




